Further evaluation of the effect of LCAT CNV on cancers with the most affected person prognosis showed that LCAT CNV is associated with the prognosis of sufferers with COAD, KICH, KIRP, pheochromocytoma and paraganglioma (PCPG), PRAD, UCEC, UVM, CESC, lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), ESCA, LGG, MESO, SARC, THCA, and THYM tumors (Figure S4). Here, LCAT is linked to prostate adenocarcinoma.